header-6.jpg
Grants

Feasibility Study - Identification of prostate cancer recurrence sites by Gallium-labelled PSMA PET/MRI in patients with biochemical recurrence following definitive therapy

The introduction of PSMA/PET scanning into prostate cancer staging has significant potential to revolutionise the imaging modalities used for primary, metastatic and recurrent disease. This novel imaging technology however is lacking robust data regarding its sensitivity and specificity and potential false positive and negative rates. This study aims to determine this with histology as well as the potential utility of PSMAPET/MRI to alter treatment plans compared to current staging imaging scans in order to potential improve detection and decrease costs. Exploratory endpoints will investigate the utility of a precision medicine approach in recurrent and metastatic prostate cancer in order to potentially direct future therapies. The primary objective of the trial is to evaluate the sensitivity and specificity of 68Ga-HBED-CC PET/MRI in detecting metastatic or locally recurrent lesions in patients with biochemical recurrence post primary treatment in comparison to staging CT, bone scan/SPECT CT and standard MRI and the relative contribution of each imaging modality to the recurrence site (bone vs soft tissue or both). 

Investigators

Dr Ian Vela APCRC-Q, PAH, IHBI, TRI

Duration

2015 - 2017